The latest disbursement underscores the Company’s role in strengthening India’s domestic pharmaceutical manufacturing ecosystemVenus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has received its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals, representing 75 percent
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combinationVenus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has secured the marketing authorization from the Indonesian regulatory authority
The approvals strengthen India’s position as a reliable supplier of advanced pharmaceuticals across ASEAN markets where Venus Remedies already exports more than 374 products. Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the 10 leading fixed-dosage injectable manufacturers in the world, has secured new marketing authorizations
VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for VRP-034 included up to 70% reduction in nephrotoxicity compared to marketed PMB The QIDP
Marketing approvals for bortezomib from Philippines and carboplatin from Morocco will enable the company to enhance its presence in ASEAN, African regionsVenus Remedies Ltd, a prominent oncology drug manufacturer, has secured marketing authorizations for two key cancer drugs, enhancing its global reach. The approvals
The UNICEF order for ceftriaxone supply is an endorsement of Venus Remedies’ exceptional quality standards and its position as a trusted partner in global healthcare supply chains The company also secures a mandate from the world's oldest international public health agency for supplying essential
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy Venus Remedies is among the largest Indian exporters of these drugs Ukraine is among the largest countries in Europe and its pharmaceutical market has been witnessing
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF This achievement is an endorsement of Venus Remedies' commitment to delivering top-quality pharmaceutical products worldwide Venus Remedies Limited, a leading global pharmaceutical company, has recently secured
The disbursement will bolster the company’s manufacturing capabilities and foster product diversification, including complex generics The grant emphasises the company’s commitment to driving innovation, entitles it to incentives for incremental sales of eligible pharmaceutical products Venus Remedies Ltd, one of India’s leading manufacturers of generic
Venus Remedies has secured regulatory approval from Philippines for chemotherapy medication paclitaxel and zoledronic acid, a drug used to treat metabolic bone disorders The company has also received marketing authorisation for another chemotherapy drug, bleomycin, from Saudi Arabia While Saudi Arabia is the largest
